Lupin announces presentation of phase 1 data on LNP7457 (PRMT5 inhibitor) at the ASCO – Annual Meeting 2025 Read more
Lupin and SteinCares enter into License and Supply Agreement for Ranibizumab in Latin America Read more
KDCA, SK bioscience launch support programme to shield South Korea against future pandemic influenza threats Read more
Alembic gains USFDA final approval for Amlodipine & Atorvastatin Tablets USP, 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, & 10 mg/80 mg Read more